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This study investigated the efficacy and safety of ear acupressure (EAP) as a stand-alone intervention for smoking cessation and
the feasibility of this study design. Adult smokers were randomised to receive EAP specific for smoking cessation (SSEAP) or a
nonspecific EAP (NSEAP) intervention which is not typically used for smoking cessation. Participants received 8 weekly treatments
andwere requested to press the five pellets taped to one ear at least three times daily. Participants were followed up for threemonths.
Primary outcome measures were a 7-day point-prevalence cessation rate confirmed by exhaled carbon monoxide and relief of
nicotine withdrawal symptoms (NWS). Intention-to-treat analysis was applied. Forty-three adult smokers were randomly assigned
to SSEAP (𝑛 = 20) or NSEAP (𝑛 = 23) groups. The dropout rate was high with 19 participants completing the treatments and 12
remaining at followup. One participant from the SSEAP group had confirmed cessation at week 8 and end of followup (5%), but
there was no difference between groups for confirmed cessation or NWS. Adverse events were few and minor.
1. Introduction
Smoking is the largest single preventable cause of death and
disease worldwide [1]. It is estimated that tobacco kills nearly
six million people annually [2]. Despite quit-smoking cam-
paigns and the availability of nicotine replacement therapy
(NRT), quit attempts are often unsuccessful [3]. Nicotine
withdrawal symptoms (NWS) including emotional distress,
depressed mood, anxiety, and sleep disturbances present
a barrier to successful smoking cessation attempts [4–6].
Increase in body weight associated with quitting smoking
may also discourage some smokers [7].
Various forms of NRT are often combined with behav-
ioural support to assist smoking cessation [8]. Other phar-
macotherapies for smoking cessation include the antidepres-
sant bupropion and the nicotine receptor partial agonist
varenicline [9]. There is evidence for the efficacy of these
therapies, but cessation rates remain relatively modest [10,
11], and the effects of interventions may last only a few
months [12]. Additionally, NRT has been associated with
increased adverse events (AEs) [13], and serious AEs have
been associatedwith varenicline and bupropion [14, 15]. Since
these pharmacotherapies do not help all smokers, there is a
need to identify and evaluate other therapeutic options and
new combinations of therapies.
Positive results have been reported for the use of ear
acupuncture/acupressure for smoking cessation. One study
(𝑛 = 141) compared a combination of true acupuncture
and education versus sham acupuncture plus education and
reported a higher cessation rate for true acupuncture which
was still evident at a 3-month followup [16]. Wing et al.
compared real ear-plus-body acupressure (𝑛 = 38) with sham
ear plus body acupressure (𝑛 = 32) in active smokers for
3 weeks with a followup at 3 months. Both groups reduced
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smoking but there were no significant differences between
groups [17]. In a study of ear acupuncture versus a sham
acupuncture treatment for 8 weeks with followups for 6
months, Wu et al. reported no difference in cessation rate,
but both groups reduced cigarette consumption and the EAP
group (𝑛 = 59) showed a significant decrease in NWS [18].
Currently the evidence for the effect of EAP for smoking
cessation is inconclusive and high quality trials with rigorous
methodologies have been recommended [19, 20].
Trials of EAP have employed a variety of designs,
acupuncture points, and methods of stimulation. In this ran-
domized participant-and-assessor-blind clinical trial, non-
invasive ear acupressure (EAP) was done on 5 points as
recommended in the literature for smoking cessation and
used in previous trials (see Protocol [21]). The control
interventionwas EAPonfive points considered as not specific
for smoking cessation.This controlwas selected because there
are a large number of acupoints on the ear, so it is difficult
to construct a control that uses nonacupoints on the ear that
is sufficiently plausible to enable effective blinding. A similar
method was used with success in an earlier study [22]. The
study aimed to investigate the efficacy and safety of this EAP
intervention for assisting smoking cessation and themanage-
ment of NWS and to determine the feasibility of this study
design.
2. Methods
The study was conducted at RMIT University, Australia,
approved by the RMIT Human Research Ethics Committee,
and registered with the Australian New Zealand Clinical
Trials Registry (no. ACTRN12611000761965), and a protocol
has been accepted for publication [21].
An independent researcher conducted block randomi-
sation using a computer generated randomisation list. The
randomised group codes were placed into sealed, opaque
envelopes by another independent person. Participants, data
entry personnel, and data analysts were blinded to treatment
allocation. The single acupuncturist was trained to perform
the same procedures at each consultation and was instructed
not to discuss any aspect of the treatment procedures with the
participants, to ensure participant blinding and consistency
of treatment.
Participant recruitment was via local newspaper adver-
tisements, posters, and the RMIT University website. Inclu-
sion criteria are aged 18 years or over, smoked >10 cigarettes
per day for one year or more, and intending to quit smoking
on the agreed date. Exclusion criteria are pathological con-
dition of the ear; wearing a hearing aid; allergy to adhesive
dressings; currently using NRT, bupropion, or varenicline;
being enrolled in another quit smoking program; other per-
sons from the same household already having been accepted
into this study; use of antidepressant or antipsychotic med-
ications; alcohol or substance abuse; pregnancy; use of ear
acupuncture or ear acupressure for a respiratory condition
and/or smoking cessation within the last 12 months; being a
student or practitioner of acupuncture, or not able to read or
understand English.
The trial comprised a 2-week run-in period, 8 weeks of
treatment, and 12 weeks of followup. At their first visit, par-
ticipants were given a thorough explanation about the study
procedure, including the 50/50 chance of being randomly
assigned to either the smoking-specific treatment group or
the nonspecific treatment group. Participants were informed
that they could choose to use NRT during the trial under
medical advice and that the use of NRT would not disqualify
them from continuing. If they agreed to participate, they
signed informed consent documents. Following the run-in
period and before the first treatment, participants randomly
selected a sealed opaque envelope with their randomisation
code inside. This allocated them to the smoking-specific-ear
acupressure (SSEAP) group or the nonspecific ear acupres-
sure (NSEAP) group. Participants selected a quit date at the
first treatment which had to be before the third treatment.
During the 8-week treatment, participants received either
SSEAP or NSEAP once per week. All participants received
stainless-steel press-pellet tapes (Magrain Pellets: Cat. no.
PELSST S/Steel Tan, supplied by Acuneeds Co., Australia)
on five EAP points. Each pellet was 1.2mm in diameter
and attached to a round adhesive tape (7mm in diameter)
in a tan colour. The skin was cleaned and sterilised with a
70% alcoholic swab. Then, pellets were taped onto one of
the participants’ ears with no skin penetration. Then, the
acupuncturist pressed each pellet for 10 seconds or until the
ear became reddish and/or slightly sore. Participants were
instructed on how to press the pellets and were requested
to press all pellets three times daily throughout the week
and whenever they felt a craving for cigarettes. At the
subsequent visit the remaining pellets were removed by the
acupuncturist and new pellets were placed on the opposite
ear. Consultations lasted approximately for 10 minutes.
In the SSEAP group the following EAP points were used:
Shenmen (TF4), Fei “lung” (CO14), Kou “mouth” (CO1),
Hunger (extra), and Gan “liver” (CO12) [23, 24]. The points
used in the NSEAP group were Lun 2 “helix 2” (HX10), Jian
“shoulder” (SF4, 5), Suogu “clavicle” (SF6), Zhen “occiput”
(AT3), and Ya “tooth” (LO1). The NSEAP ear points are not
typically used for smoking cessation or respiratory conditions
[23, 24].
The Fagerstrom Test for Nicotine Dependence was
administered at baseline to assess the equivalence of groups
[25]. To assess participants’ determination to quit smoking,
the Contemplation Ladder was administered at baseline, end
of treatment, and end of followup [26]. Self-report data on
NWS, cigarette consumption, NRT usage, and AEs were
collected usingCaseReport Forms (CRFs)which participants
completed daily throughout the study period.
Primary outcome 1 was smoking cessation. Successful
cessation was defined as a 7-day point prevalence (no smok-
ing over 7 consecutive days) [27] measured by participant
self-report and validated by two consecutive exhaled carbon
monoxide (CO) concentration readings of ≤10 ppm using the
piCO+ Smokerlyser (Bedfont Scientific Ltd., Upchurch, Kent,
UK). Exhaled COmeasurements were conducted at each visit
and recorded in the CRF (visit 1–visit 10).
Primary outcome 2 was NWS assessed using the Mood
and Physical Symptoms Scale (MPSS) in which participants
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rate the severity of depression, irritability, restlessness,
hunger, poor concentration, anxiety, insomnia, frequency
and levels of smoking urges, and physical symptoms such as
mouth sores, constipation, and cough or sore throat [28]. All
questions had scoring range of 1–5 (low to high) except for
Questions 8 and 9 (frequency and levels of smoking urges)
which scored 0–5.
Secondary outcome measures included (1) NRT usage
throughout the trial; (2) daily consumption of cigarettes; (3)
body weight (measured each time the participant was on
site); and (4) quality of life using the Short-Form 36v2 Health
Survey (1992, 2003 Health Assessment Lab, Medical Out-
comes Trust andQualityMetric Incorporated, USA) at initial
assessment, end of treatment, and end of followup periods.
All participants were asked to record in their CRFs any
unpleasant experience throughout the trial and to assess
whether the AEwas related to the EAP. Participants answered
a question on the CRF at the end of the first and the last
treatment weeks regarding which group they perceived that
they had been allocated into.
Statistical Analysis. Statistical Package for the Social Sciences
software version 18.0 (SPSS Inc., Chicago, Ill, USA) was
used for analyses. Quality Metric Health Outcomes Scor-
ing Software 4.0 was used for SF36 scores (2010 Quality
Metric Incorporated, USA). Intention-to-treat analysis was
applied with missing data being managed using expectation
maximisation. Baseline characteristics of the groups were
assessed using unpaired 𝑡-tests and 𝜒2 tests for equivalence.
For primary and secondary outcome measures, unpaired 𝑡-
tests or general linear model (GLM) was used as appropriate
to compare group differences. The randomisation code was
broken after the analysis of outcomemeasureswas completed.
3. Results
Ninety-five (95) smokers were screened for eligibility for this
study, eighteen did not meet inclusion criteria, 10 declined
to participate, 12 were unable to participate due to various
reasons (work, distance to trial site, overseas travel, and
illness), and 12 participants were not contactable after the
screening process (Figure 1).
Forty-three participants were randomised into the SSEAP
group (𝑛 = 20) or the NSEAP group (𝑛 = 23). At the end
of treatment week 8, 19 participants remained in the study
and 12 remained till the end of followup. Thirteen dropouts
gave no reason and were lost to contact. For those who gave
a reason (𝑛 = 18), the most common was “too much going
on” (𝑛 = 8) followed by 5 who dropped out because of travel.
Four people in the NSEAP group reported that the treatment
was ineffective, and one person in this group gave discomfort
with ear pellets as the reason for dropping out (Figure 1).
At baseline, no significant differences between the two
groups were found on gender, age, marital status, education
level, and country of birth (Table 1). Comparison of partici-
pants’ smoking history, presence of other household smokers,
mean scores on Fagerstrom Test for Nicotine Dependence,
mean scores for the Contemplation Ladder, exhaled CO,
and body weight were not significantly different between
groups. Nicotine dependence was medium to high in 86% of
participants and all but two had made previous attempts to
quit smoking. SF36 scores showed no significant differences
between the groups for physical or mental components.
3.1. Smoking Cessation. During the treatment period, the
CO-confirmed (10 ppm) 7-day-point prevalence cessation
was three participants, one from the SSEAP group and
two from the NSEAP group with no significant difference
between groups (𝜒2 = 0.225, 𝑃 = 0.635). By the end of
treatment, the two confirmed quitters in the NSEAP group
had dropped out and were lost to followup. At three-month
followup, the one participant from the SSEAP group had
continued to abstain from smoking (CO confirmed), so the
cessation rates were 5% for SSEAP and 0% for NSEAP at
end of treatment and at end of followup. A post hoc analysis
using a CO threshold of 7 ppm, which was at the lower end of
the manufacturer’s recommended range for the Smokerlyser,
excluded one quitter from the NSEAP group but did not
change the overall result.
3.2. Nicotine Withdrawal Symptoms. All MPSS scores were
low at baseline. At baseline, there were significant differences
between groups on the mean MPSS scores for Question 8
“frequency of urges to smoke” (𝑡 = −3.302, df = 41, and
𝑃 = 0.002) and Question 9 “magnitude of urges to smoke”
(𝑡 = −2.760, df = 41, 𝑃 = 0.009). These two scores were used
as covariates in a GLM analysis for these two questions to
adjust to this difference. At the end of treatment and at the
end of followup, therewere no significant differences between
the two groups for any of the NWS measured by MPSS.
3.3. NRT Usage. NRT usage was allowed, but only one par-
ticipant from the SSEAP group reported NRT use. This
participant did not quit or reduce cigarette consumption.
3.4. Cigarette Consumption. Based on participants’ self-
report, the mean daily cigarette consumption decreased from
baseline to the end of treatment in both the SSEAP (15.14 ±
7.44, 10.61 ± 7.56) and NSEAP (19.11 ± 6.85, 12.32 ± 5.47)
groups. The decreases were 30.0% and 35.5%, respectively.
At the end of treatment, there was no significant difference
between groups in cigarette consumption (𝑡 = −0.857, df =
41, 𝑃 = 0.397). At the end of followup, consumption had
increased compared with the end of treatment (SSEAP 14.5±
4.57 versus NSEAP 17.76 ± 5.03), but both groups remained
lower than their respective baselines. A small but significant
difference was found between groups (𝑡 = −2.203, df = 41,
𝑃 = 0.033) at the end of followup.
3.5. Change in Body Weight. The mean individual change in
body weight compared to baseline was not significantly
different between groups at the end of treatment (SSEAP =
5.37 ± 9.38, NSEAP = −1.30 ± 14.09, 𝑡 = 1.797, df = 41,
𝑃 = 0.08) or at the end of followup (SSEAP = 6.80 ± 10.44,
NSEAP = −0.17 ± 14.82, 𝑡 = 1.754, df = 41, 𝑃 = 0.087).
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Participant recruitment
8-week treatement period 8-week treatment period
2-week run-in period 
for eligible participants
Number of enquires (n = 114)
Assessed for eligibility (n = 95) Excluded (n = 52):
Randomised (n = 43)
Smoking-specific ear acupressure group (n = 20)
Dropped out during 8-week treatment period
(n = 9):
too much going on (n = 4)
travel for leisure (n = 2)
no reason (n = 3).
12-week followup period
Smoking-specific ear acupressure group (n = 11)
Lost to followup no reason (n = 4)
Analysed (n = 20) Analysed (n = 23)
Nonspecific ear acupressure group (n = 23)
Dropped out during 8-week treatment period
(n = 15):
n = 1)
n = 4)
n = 3)
n = 2)
discomfort with ear pellets (
ineffective treatment (
too much going on (
travel for work or leisure (
no reason (n = 5).
12-week followup period
Nonspecific ear acupressure group (n = 8)
Lost to followup (n = 3):
no reason (n = 1), travel (n = 1), and too much going
on (n = 1)
Not meeting inclusion criteria (n = 18)
Smokes less than 10 cigs/day (n = 4)
Hearing aid (n = 1)
Taking antidepressant or antipsychotics (n = 11)
Joined hypnotherapy (n = 1)
Hepatitis (n = 1)
Unable to attend due to work, travel, and illness or
distance to site (n = 12)
Declined to participate (n = 10)
No reason (n = 12)
Figure 1: Participant recruitment and trial procedure.
3.6. Quality of Life. There were no significant differences
between the SSEAP and NSEAP groups on the physical
(SSEAP = 49.30±6.92, NSEAP = 49.41±3.91, 𝑡 = −0.07, df =
41, 𝑃 = 0.945) or mental component scores (SSEAP = 48.83±
5.44, NSEAP = 48.05 ± 4.55, 𝑡 = 0.472, df = 41, 𝑃 = 0.612)
of SF36v2 at end of treatment. Also, at the end of followup,
no group differences were found on the physical (SSEAP =
49.27 ± 5.52, NSEAP = 47.97 ± 3.05, 𝑡 = 0.967, df = 41, 𝑃 =
0.339) or mental component scores (SSEAP = 55.01 ± 2.81,
NSEAP = 53.77 ± 4.45, 𝑡 = 1.071, df = 41, 𝑃 = 0.29).
3.7. Credibility of Blinding. There was no significant differ-
ence between the two groups in participants’ perception of
group allocation at the end of the first treatment week (𝜒2 =
5.035, df = 2, 𝑃 = 0.081) or at the end of treatment week
8 (𝜒2 = 3.753, df = 2, 𝑃 = 0.153). Also, participant’s belief
regarding their group allocation did not significantly affect
whether they dropped out or not.
3.8. Adverse Events (AEs). All AEs (1 event from one SSEAP
participant and 5 from four NSEAP participants) were mild
or moderate, but one participant dropped out for discomfort
with the ear pellets. The most frequent AEs were mild to
moderate discomfort on the ear (1 in SSEAP and 4 inNSEAP).
Participants reported that these AEs were “probably due to
the EAP.” One participant in the NSEAP group reported
slight headache and dizziness (1 event). All AEs were resolved
without any medical intervention.
4. Discussion
This study compared the effects of an SSEAP intervention
to an NSEAP intervention in adult smokers who wished
to stop smoking. We employed the 7-day point-prevalence
method to calculate cessation rate. One participant from
the SSEAP group (5%) and 2 participants from the NSEAP
group had quit smoking (8.7%) by the end of treatment.
However, the only confirmed quitter at the end of treatment
and at 3 months of followup was the SSEAP participant,
since the two NSEAP participants did not continue in the
study and all dropouts were considered as smokers in the ITT
analysis.
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Table 1: Baseline data for smoking-specific and nonspecific ear acupressure groups.
Smoking-specific
ear acupressure group,
n or mean ± SD
(𝑁 = 20)
Nonspecific
ear acupressure group,
n or mean ± SD
(𝑁 = 23)
t-test or Chi-square test results
Gender
Male 8 10
𝜒
2
= 0.053, 𝑃 = 0.818
Female 12 13
Age (years) 50.4 ± 11.49 49.8 ± 8.53
𝑡 = 0.202, df = 41, 𝑃 = 0.841
(range) (29–69) (27–68)
Marital status
Single 5 7
𝜒
2
= 2.446, 𝑃 = 0.294Married/partnered 13 16
Separated 2 0
Educational level
High school 11 18
𝜒
2
= 3.408, 𝑃 = 0.182TAFE 4 1
University or more 5 4
Country of birth
Australia 14 16
𝜒
2
= 0.001, 𝑃 = 0.975
Outside Australia 6 7
Age at the first cigarette 16.3 ± 3.66 16.35 ± 6.27 𝑡 = −0.303, df = 41, 𝑃 = 0.976
No. of years smoking 34.05 ± 11.11 33.87 ± 9.07 𝑡 = 0.059, df = 41, 𝑃 = 0.954
Previous attempts to quit
Yes 20 21
𝜒
2
= 1.824, 𝑃 = 0.177
No 0 2
Other smoker(s) at home
Yes 5 11
𝜒
2
= 2.386, 𝑃 = 0.122
No 15 12
Karl Fagerstrom Test for
Nicotine Dependence
Score
Low 4 2
𝜒
2
= 2.522, 𝑃 = 0.283Medium 10 9
High 6 12
Contemplation Ladder 9.4 ± 1.35 9.17 ± 1.75 𝑡 = 0.469, df = 41, 𝑃 = 0.642
Smoking rate/day (no. of
cigs) 15.14 ± 7.44 19.11 ± 6.85 𝑡 = −1.189, df = 41, 𝑃 = 0.076
Total no. of cigs smoked
in one week 106 ± 52.11 132.3 ± 48.69 𝑡 = −1.170, df = 41, 𝑃 = 0.095
COmeasurement (ppm) 23.4 ± 9.02 24.65 ± 10.27 𝑡 = −0.422, df = 41, 𝑃 = 0.675
Body weight (kg) 71.08 ± 13.47 77.99 ± 18.82 𝑡 = −1.345, df = 41, 𝑃 = 0.186
SF36 scores
Physical component 45.97 ± 9.87 44.39 ± 9.22 𝑡 = 0.540, df = 41, 𝑃 = 0.592
Mental component 46.32 ± 12.07 46.88 ± 11.01 𝑡 = −0.161, df = 41, 𝑃 = 0.873
Randomised trials of over-the-counter NRT patch versus
placebo patch have reported successful quit rates of 5.6% to
15% in the treatment groups [3, 29–31]. Results from this
study are at the lower end of this range. One possible reason
for a low success rate in smoking trials is that these clinical
trials tend to attract smokers who have already found it
difficult to stop [32]. Notably, 95% of our study participants
had previously tried to quit smoking and failed. Before
trial commencement, we assessed participants’ motivation
to stop smoking using the Contemplation Ladder. Almost
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all participants (41/43) were determined to quit, but only 10
completed the study. In this study, highmotivation to quit did
not ensure success of quitting or indicate that the participant
would complete the study.
High dropout rates in smoking cessation studies are not
unusual [10]. Bier et al. in 2002 compared the effect on
smoking cessation of EAP alone and in combination with
education. During the 18-month trial period, the participants’
numbers dropped from 141 to 48 [16]. Another study that
compared the effect of NRT in combination with EAP had
7 out of 19 participants who completed the study [4]. Several
factorsmay have contributed to the dropout rate in this study.
Smokers committed to the study in good faith and aimed to
quit smoking, but some reported that they stopped coming
due to “too much happening in their lives,” or travel for work
or leisure. Participants were required to visit the trial site
weekly throughout the treatment period and were required
to fill out the CRF daily. These demands on their time
may have contributed to the high dropout rate, but we did
not receive any feedback confirming this. We observed that
participants frequently expressed how difficult it was to quit
smoking and wished to discuss their experiences. However,
due to the nature of acupuncture, the acupuncturist could
not be blinded and therefore was instructed to have minimal
interaction with participants. Therefore, participants may
not have felt supported in their quit efforts. Counselling is
widely available in Australia via helplines, and participants
were advised to consult, their general practitioner, but future
studies should include a form of support as part of the trial.
No differences in NWS were found between groups. The
mean NWS scores were very low at baseline and throughout
the trial. This could mean that the participants were not
diligent in recording their NWS in the CRFs or that many
participants did notmake attempts to quit on their designated
quit day. Post hoc investigation of the individual data found
that the known quitters (𝑛 = 3) showed short-term increases
in their scores for questions which measured cigarette crav-
ings, whereas the known nonquitters showed little change.
Therefore, change in the MPSS indicated the presence of
individual cessation attempts at particular time points, so
MPSS was found to be sensitive to changes in cigarette
cravings. However, these changes were not detectable in
the consolidated data because they lasted for short periods
and occurred at different time points. In future trials a
different approach to assessing NWS between groups should
be considered.
There was an overall reduction in cigarette consumption.
For those participants who completed the treatment period,
in the SSEAP group (𝑛 = 11), one participant reduced his/her
daily cigarette consumption by 75% compared to baseline,
two participants reduced it by 47%, and one participant
reduced it by 42%. In the NSEAP group (𝑛 = 8), one
participant reduced his/her daily cigarette consumption by
32%, while another participant achieved a reduction rate of
15%. It is interesting to note that although most participants
did not quit smoking, those receiving the SSEAP treatment
showed a greater reduction in the number of cigarettes they
smoked during the treatment period and a less pronounced
rebound during followup. Cutting down is a step towards
complete cessation [33]; therefore, EAP use may assist in
reducing to quit. Similarly, a trial that compared active ear-
plus-body acupressure with sham ear-plus-body acupressure
in active smokers found that cigarette consumption was
reduced [17].
Although one participant dropped out for discomfort
with the ear pellets, AEs were all mild or moderate. Previous
studies that employed a similar EAP protocol for persistent
allergic rhinitis [22, 34] and smoking cessation [4, 17] found
that EAP was well tolerated by participants.
Issues with Study Design and Implementation. Stainless-steel
press-pellet tapes commonly used by Chinese medicine
practitioners were used in the trial. Participants commented
that the metal balls moved to a different spot after being
pressed in between visits. Due to the small area of the ear
and large number of acupuncture points, movement of the
metal ball can mean that the participant has moved the pellet
away from the ear point. This may have affected the results
in the SSEAP group. White et al. in 2007 reported that ear
pellets could become detached from the ear due to loss of
adhesion [4]. Therefore, we took care to ensure that the skin
was clean and pellet adhesion was good. The average weekly
pellet loss was 17–24% which is approximately one pellet per
week.While pellet loss was not a major issue, movement may
have had an equivalent effect. Therefore, one week may be an
unrealistically long time to expect the pellets to remain on the
correct points, when the participants are repeatedly pressing
them each day.
The dropout rate was a concern, and it affected the results
since ITT analysis was used, and this required the imputation
of a large number of data points based on conservative
estimates. It was not possible to definitively determine the
reasons for the high dropout rate, but the requirement to
complete a series of questions on the CRF daily (two pages)
could have been perceived as onerous, and participants may
not have carefully considered their responses to questions.
Therefore, reduction in the number of secondary outcome
measures may assist in compliance and may also provide
better accuracy in reporting. No support or counselling was
provided during the trial, although this was available to
participants via helplines or their GPs. This aimed to isolate
the effect of the EAP and not to introduce an additional
source of variation, but future studies should use a more
pragmatic intervention that includes a form of support
provided by an independent person blind to treatment
allocation.
The ear points were selected based on existing literature
and use in other clinical trials [21]. In general, the point “lung”
is used for lung disorders, and “shenmen” is used to calm
the mind. “Liver” is for liver dysfunction and stress, while
“mouth” and “hunger” aim to reduce cravings.However, there
is no single well-established EAP treatment for smoking, so
the points selected mainly aimed to reduce NWS and stress.
Thenonspecific control points have a range of uses. For exam-
ple, “shoulder” (Jian) is used for shoulder pain and shoulder
tension, and “occiput” is used for neurological disorders and
for sedation. Therefore, this NSEAP treatment cannot be
considered a form of placebo, and some of these points could
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be indirectly beneficial for general stress and/or the relief of
some symptoms associated with smoking cessation.
5. Conclusion
This study followed a rigorous methodological protocol,
and blinding of participants was successful. Consistent with
previous acupressure studies, only minor adverse events
were reported. Dropout rates were high in both groups.
ITT analysis found that after 8 weeks of treatment, the 7-
day point prevalence, CO-confirmed quit rate in the SSEAP
group was 5%, and this continued at three months after
treatment, but there was no significant differences between
groups. Cigarette consumption declined in both groups over
the treatment period.Thedecline appearedmore pronounced
in the SSEAP group and therewas a small statistical difference
at followup. NRT usage was low throughout. There was no
apparent effect on NWS in either group, but the method
used appears unsuitable for detecting between group changes.
Future studies should address the design issues found in this
trial and investigate continuous abstinence and long-term
cessation rate at 6 months.
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